신경계 질환에서 철 관련 자기공명영상 기법의 활용 = Application of Iron Related Magnetic Resonance Imaging in the Neurological Disorders

다국어 초록 (Multilingual Abstract)

Iron is an important element for brain oxygen transport, myelination, DNA synthesis and neurotransmission. However,excessive iron can generate reactive oxygen species and contribute neurotoxicity. Although brain iron deposition is thenatural process with normal aging, excessive iron accumulation is also observed in various neurological disorders suchas neurodegeneration with brain iron accumulation, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Friedreichataxia, and others. Magnetic resonance image (MRI) is a useful method for detecting iron deposits in the brain. It canbe a powerful tool for diagnosis and monitoring, while furthering our understanding of the role of iron in the pathophysiologyof a disease. In this review, we will introduce the mechanism of iron toxicity and the basics of severaliron-related MRI techniques. Also, we will summarize the previous results concerning the clinical application of suchMR imagings in various neurological disorders. (Korean J Clin Neurophysiol 2014;16:1-7)

참고문헌 (Reference)

1 Han YH, "Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy" 325 : 29-35, 2013

2 Zecca L, "The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging" 101 : 9843-9848, 2004

3 Sian-Hülsmann J, "The relevance of iron in the pathogenesis of Parkinson's disease" 118 : 939-957, 2011

4 Kumar N, "The "eye-of-the-tiger" sign is not pathognomonic of the PANK2mutation" 63 : 292-293, 2006

5 McNeill A, "T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation" 70 : 1614-1619, 2008

6 Mittal S, "Susceptibilityweighted imaging: technical aspects and clinical applications, part 2" 30 : 232-252, 2009

7 Haacke EM, "Susceptibility-weighted imaging: technical aspects and clinical applications, part 1" 30 : 19-30, 2009

8 Walsh AJ, "Susceptibility phase imaging with comparison to R2 mapping of iron-rich deep grey matter" 57 : 452-461, 2011

9 Boddaert N, "Selective iron chelation in Friedreich ataxia: biologic and clinical implications" 110 : 401-408, 2007

10 Vinod Desai S, "Relaxation and susceptibility MRI characteristics in Hallervorden-Spatz syndrome" 25 : 715-720, 2007

11 Rottkamp CA, "Redox-active iron mediates amyloid-beta toxicity" 30 : 447-450, 2001

12 Lee JH, "Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy" 260 : 2094-2101, 2013

13 Zhu WZ, "Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease" 253 : 497-504, 2009

14 Langkammer C, "Quantitative MR imaging of brain iron: a postmortem validation study" 257 : 455-462, 2010

15 House MJ, "Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss" 27 : 430-439, 2006

16 Bermel RA, "Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity" 62 : 1371-1376, 2005

17 Honda K, "Oxidative stress and redox-active iron in Alzheimer's disease" 1012 : 179-182, 2004

18 Lee JH, "Nigropallidal iron accumulation in pantothenate kinase-associated neurodegeneration demonstrated by susceptibility-weighted imaging" 257 : 661-662, 2010

19 Schipper HM, "Neurodegeneration with brain iron accumulation-clinical syndromes and neuroimaging" 1822 : 350-360, 2012

20 Schenck JF, "Magnetic resonance imaging of brain iron" 207 : 99-102, 2003

21 Westbrook C, "MRI in practice" Wiley-Blackwell 21-34, 2011

22 Bartzokis G, "MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects" 17 : 213-222, 1999

23 Ropele S, "MRI assessment of iron deposition in multiple sclerosis" 34 : 13-21, 2011

24 Gelman N, "MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content" 210 : 759-767, 1999

25 Bartzokis G, "MR evaluation of age-related increase of brain iron in young adult and older normal males" 15 : 29-35, 1997

26 Baraibar MA, "Ironmediated aggregation and a localized structural change characterize ferritin from a mutant light chain polypeptide that causes neurodegeneration" 283 : 31679-31689, 2008

27 Zecca L, "Iron, brain ageing and neurodegenerative disorders" 5 : 863-873, 2004

28 Berg D, "Iron metabolism in Parkinsonian syndromes" 21 : 1299-1310, 2006

29 Stankiewicz J, "Iron in chronic brain disorders: imaging and neurotherapeutic implications" 4 : 371-386, 2007

30 Dusek P, "Iron dysregulation in movement disorders" 46 : 1-18, 2012

31 LeVine SM, "Iron deposits in multiple sclerosis and Alzheimer's disease brains" 760 : 298-303, 1997

32 Gutteridge JM, "Iron and oxygen radicals in brain" 32 Suppl : S16-S21, 1992

33 Gorell JM, "Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease" 45 : 1138-1143, 1995

34 Raven EP, "Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging" 37 : 127-136, 2013

35 Waldvogel D, "Increased iron in the dentate nucleus of patients with Friedrich's ataxia" 46 : 123-125, 1999

36 Bartzokis G, "In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging" 57 : 47-53, 2000

37 Du G, "Imaging nigral pathology and clinical progression in Parkinson's disease" 27 : 1636-1643, 2012

38 Haacke EM, "Imaging iron stores in the brain using magnetic resonance imagin" 23 : 1-25, 2005

39 Bartzokis G, "Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores" 29 : 459-464, 1993

40 Lee JH, "Evaluation of brain iron content in idiopathic REM sleep behavior disorder using quantitative magnetic resonance imaging"

41 Yan SQ, "Evaluation of brain iron content based on magnetic resonance imaging (MRI):comparison among phase value, R2* and magnitude signal intensity" 7 : e31748-, 2012

42 Morawski M, "Determination of trace elements in the human substantia nigra" 231 : 224-228, 2005

43 Ropele S, "Determinants of iron accumulation in deep grey matter of multiple sclerosis patients" 2014

44 Jin L, "Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease" 134 : 50-58, 2011

45 House MJ, "Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients" 57 : 172-180, 2007

46 van der Kolk AG, "Clinical applications of 7 T MRI in the brain" 82 : 708-718, 2013

47 Gregory A, "Clinical and genetic delineation of neurodegeneration with brain iron accumulation" 46 : 73-80, 2009

48 Zhang J, "Characterizing iron deposition in Parkinson's disease using susceptibilityweighted imaging: an in vivo MR study" 1330 : 124-130, 2010

49 Crichton RR, "Brain iron metabolism and its perturbation in neurological diseases" 118 : 301-314, 2011

50 Benarroch EE, "Brain iron homeostasis and neurodegenerative disease" 72 : 1436-1440, 2009

51 Graham JM, "Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence" 123 : 2423-2431, 2000

52 Ignjatović A, "Brain iron MRI: a biomarker for amyotrophic lateral sclerosis" 38 : 1472-1479, 2013

53 Mantyh PW, "Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide" 61 : 1171-1174, 1993

54 Aquino D, "Age-related iron deposition in the basal ganglia:quantitative analysis in healthy subjects" 252 : 165-172, 2009